Aktieanalys

Cantargia: Comments on CAN10’s toxicity study and the share price rally - Redeye

{newsItem.title}

Redeye Publicerad: 16 Jan 2023 08:20

Redeye is favourable towards the new preclinical results with CAN10 but believes that the share price rally on Friday, and this year in general, is more due to volatility than due to any news affecting fundamentals.

Länk till analysen i sin helhet: https://www.redeye.se/research/870949/cantargia-comments-on-can10s-toxicity-study-and-the-share-price-rally?utm_source=finwire&utm_medium=RSS

Nyheter om Cantargia

Läses av andra just nu

Om aktien Cantargia

Senaste nytt